{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,8,2]],"date-time":"2025-08-02T16:42:59Z","timestamp":1754152979915,"version":"3.41.2"},"reference-count":21,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/501100013395","name":"Sistema Nacional de Investigadores","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100013395","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003141","name":"Consejo Nacional de Humanidades, Ciencias y Tecnolog\u00edas","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100003141","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Archives of Medical Research"],"published-print":{"date-parts":[[2025,7]]},"DOI":"10.1016\/j.arcmed.2025.103207","type":"journal-article","created":{"date-parts":[[2025,3,25]],"date-time":"2025-03-25T07:45:27Z","timestamp":1742888727000},"page":"103207","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["Extraosseous Plasmacytoma Confers Poor Outcomes in Primary Plasma Cell Leukemia"],"prefix":"10.1016","volume":"56","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8070-0415","authenticated-orcid":false,"given":"Jorge","family":"Vela-Ojeda","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5210-953X","authenticated-orcid":false,"given":"Aline","family":"Ramirez-Alvarado","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ana Sofia","family":"Sanchez-Rodriguez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jaime","family":"Garcia-Chavez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Laura Arcelia","family":"Montiel-Cervantes","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.arcmed.2025.103207_bib0001","doi-asserted-by":"crossref","first-page":"1062","DOI":"10.1016\/0002-9343(87)90942-9","article-title":"Plasma cell leukemia: an evaluation of response to therapy","volume":"83","author":"Noel","year":"1987","journal-title":"Am J Med"},{"key":"10.1016\/j.arcmed.2025.103207_bib0002","doi-asserted-by":"crossref","first-page":"907","DOI":"10.1182\/blood-2014-03-565051","article-title":"Trends in survival of patients with primary plasma cell leukemia: a population-based analysis","volume":"124","author":"Gonsalves","year":"2014","journal-title":"Blood"},{"key":"10.1016\/j.arcmed.2025.103207_bib0003","doi-asserted-by":"crossref","first-page":"813","DOI":"10.1001\/archinte.133.5.813","article-title":"Plasma cell leukemia. Report on 17 cases","volume":"133","author":"Kyle","year":"1974","journal-title":"Arch Intern Med"},{"key":"10.1016\/j.arcmed.2025.103207_bib0004","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1038\/s41408-021-00587-0","article-title":"Primary plasma cell leukemia: consensus definition by the International Myeloma Working Group according to peripheral blood plasma cell percentage","volume":"11","author":"Fern\u00e1ndez de Larrea","year":"2021","journal-title":"Blood Cancer J"},{"key":"10.1016\/j.arcmed.2025.103207_bib0005","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1016\/j.blre.2011.01.005","article-title":"Plasma cell leukemia","volume":"25","author":"Albarracin","year":"2011","journal-title":"Blood Rev"},{"key":"10.1016\/j.arcmed.2025.103207_bib0006","doi-asserted-by":"crossref","first-page":"1144","DOI":"10.1016\/j.bbmt.2013.02.003","article-title":"Therapeutic advances in the treatment of primary plasma cell leukemia: a focus on hematopoietic cell transplantation","volume":"19","author":"Nishihori","year":"2013","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.arcmed.2025.103207_bib0007","doi-asserted-by":"crossref","first-page":"3412","DOI":"10.1200\/JCO.2005.04.242","article-title":"International staging system for multiple myeloma","volume":"23","author":"Greipp","year":"2005","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.arcmed.2025.103207_bib0008","doi-asserted-by":"crossref","first-page":"e328","DOI":"10.1016\/S1470-2045(16)30206-6","article-title":"International Myeloma Working Group consensus criteria for response and minimal residual disease assessment in multiple myeloma","volume":"17","author":"Kumar","year":"2016","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.arcmed.2025.103207_bib0009","doi-asserted-by":"crossref","first-page":"1628","DOI":"10.1093\/annonc\/mdq646","article-title":"Primary plasma cell leukemia: a retrospective multicenter study of 73 patients","volume":"22","author":"Pagano","year":"2011","journal-title":"Ann Oncol"},{"key":"10.1016\/j.arcmed.2025.103207_bib0010","doi-asserted-by":"crossref","first-page":"804","DOI":"10.3324\/haematol.2009.013334","article-title":"Primary plasma cell leukemia and autologous stem cell transplantation","volume":"95","author":"Drake","year":"2010","journal-title":"Haematologica"},{"key":"10.1016\/j.arcmed.2025.103207_bib0011","doi-asserted-by":"crossref","first-page":"780","DOI":"10.1038\/leu.2012.336","volume":"27","author":"Fernandez de Larrea","year":"2013","journal-title":"Leukemia"},{"key":"10.1016\/j.arcmed.2025.103207_bib0012","doi-asserted-by":"crossref","first-page":"2125","DOI":"10.1200\/JCO.2015.63.1929","article-title":"Bortezomib, doxorubicin, cyclophosphamide, dexamethasone induction followed by stem cell transplantation for primary plasma cell leukemia: a prospective phase II study of the Intergroupe Francophone Du Myelome","volume":"34","author":"Royer","year":"2016","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.arcmed.2025.103207_bib0013","doi-asserted-by":"crossref","first-page":"1119","DOI":"10.1016\/S1470-2045(23)00405-9","article-title":"Treatment of primary plasma cell leukaemia with carfilzomib and lenalidomide-based therapy (EMN12\/HOVON-129): final analysis of a non-randomised, multicenter, phase 2 study","volume":"24","author":"Van de Donk","year":"2023","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.arcmed.2025.103207_bib0014","doi-asserted-by":"crossref","first-page":"3945","DOI":"10.1200\/JCO.22.02567","article-title":"Daratumumab, cyclophosphamide, bortezomib, lenalidomide, and dexamethasone as induction and extended consolidation improve outcome in ultra-high-risk multiple myeloma","volume":"41","author":"Kaiser","year":"2023","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.arcmed.2025.103207_bib0015","article-title":"Plasma cell leukemia with successful upfront venetoclax in combination with allogeneic transplantation","volume":"24","author":"On Tang","year":"2023","journal-title":"Am J Case Rep"},{"key":"10.1016\/j.arcmed.2025.103207_bib0016","doi-asserted-by":"crossref","first-page":"e346","DOI":"10.1002\/ctm2.346","article-title":"A phase I study of anti-BCMA CAR T cell therapy in relapsed\/refractory multiple myeloma and plasma cell leukemia","volume":"11","author":"Li","year":"2021","journal-title":"Clin Transl Med"},{"key":"10.1016\/j.arcmed.2025.103207_bib0017","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1007\/s00277-008-0554-0","article-title":"Multiple myeloma-associated amyloidosis is an independent high-risk prognostic factor","volume":"88","author":"Vela-Ojeda","year":"2009","journal-title":"Ann Hematol"},{"key":"10.1016\/j.arcmed.2025.103207_bib0018","doi-asserted-by":"crossref","first-page":"362","DOI":"10.1007\/s00277-002-0480-5","article-title":"Intermediate doses of melphalan and dexamethasone are better than vincristine, adriamycin, and dexamethasone (VAD) and polychemotherapy for the treatment of primary plasma cell leukemia","volume":"81","author":"Vela-Ojeda","year":"2002","journal-title":"Ann Hematol"},{"key":"10.1016\/j.arcmed.2025.103207_bib0019","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1038\/s41408-022-00755-w","article-title":"Validation of the revised diagnostic criteria for primary plasma cell leukemia by the Korean multiple myeloma Working Party","volume":"12","author":"Jung","year":"2022","journal-title":"Blood Cancer J"},{"key":"10.1016\/j.arcmed.2025.103207_bib0020","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1002\/(SICI)1096-8652(199912)62:4<228::AID-AJH5>3.0.CO;2-3","article-title":"Cerebral and meningeal multiple myeloma after autologous stem cell transplantation. A case report and review of the literature","volume":"62","author":"Petersen","year":"1999","journal-title":"Am J Hematol"},{"key":"10.1016\/j.arcmed.2025.103207_bib0021","doi-asserted-by":"crossref","first-page":"816","DOI":"10.1080\/10428194.2023.2171266","article-title":"Primary plasma cell leukemia in Latin America: demographic, and prognostic characteristics. A study of GELAMM group","volume":"64","author":"Pe\u00f1a","year":"2023","journal-title":"Leuk Lymph"}],"container-title":["Archives of Medical Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S018844092500027X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S018844092500027X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,7,22]],"date-time":"2025-07-22T14:18:53Z","timestamp":1753193933000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S018844092500027X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7]]},"references-count":21,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2025,7]]}},"alternative-id":["S018844092500027X"],"URL":"https:\/\/doi.org\/10.1016\/j.arcmed.2025.103207","relation":{},"ISSN":["0188-4409"],"issn-type":[{"type":"print","value":"0188-4409"}],"subject":[],"published":{"date-parts":[[2025,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Extraosseous Plasmacytoma Confers Poor Outcomes in Primary Plasma Cell Leukemia","name":"articletitle","label":"Article Title"},{"value":"Archives of Medical Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.arcmed.2025.103207","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Instituto Mexicano del Seguro Social (IMSS). Published by Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"103207"}}